Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Foghorn Therapeutics Inc (NQ: FHTX ) 7.745 -0.035 (-0.45%) Streaming Delayed Price Updated: 3:17 PM EDT, Oct 8, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Foghorn Therapeutics Inc < Previous 1 2 3 4 5 Next > Foghorn Therapeutics to Participate in the BMO Oncology Summit October 01, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Strengthens Leadership Team with Appointment of Anna Rivkin, Ph.D. as Chief Business Officer September 03, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Participate in Two Upcoming Investor Conferences in September August 28, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics: Q4 Earnings Insights March 07, 2024 Via Benzinga Why Nikola Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Monday's Mid-Day Session August 19, 2024 Via Benzinga ZIM Integrated Shipping Services Posts Upbeat Earnings, Joins fuboTV, Foghorn Therapeutics And Other Big Stocks Moving Higher On Monday August 19, 2024 Via Benzinga FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q2 2024 August 08, 2024 FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. Via InvestorPlace Foghorn Therapeutics Provides Second Quarter 2024 Financial and Corporate Update August 08, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June May 28, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline May 22, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants May 20, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Misses Revenue for Q1 2024 May 06, 2024 FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. Via InvestorPlace Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update May 06, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Strengthens Financial Leadership with Appointment of Kristian Humer as Chief Financial Officer April 16, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Presents New Preclinical Data on Potential First-in-Class BRM Selective Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Oncology Programs April 09, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Participate in Needham’s 23rd Annual Virtual Healthcare Conference April 05, 2024 Company presentation and fireside chat on April 11th at 11:45 a.m. ET From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn to Host Conference Call and Webcast on Pipeline of Potential First-in-Class Medicines in Conjunction with the 2024 AACR Annual Meeting March 26, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire FHTX Stock Earnings: Foghorn Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 07, 2024 FHTX stock results show that Foghorn Therapeutics beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. Via InvestorPlace Foghorn Therapeutics Provides Financial Update for 2023 and 2024 Strategic Outlook March 07, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Present New Preclinical Data at 2024 AACR Annual Meeting, Reflecting Advances with Multiple Potential First-in-Class Medicines, including the Selective Inhibitor of BRM, FHD-909 March 05, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Participate in Cowen’s 44th Annual Health Care Conference February 28, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Thursday's Intraday Session February 08, 2024 Via Benzinga Why Foghorn Therapeutics (FHTX) Stock Is Exploding Higher February 08, 2024 Foghorn Therapeutics shares are trading higher by 44.8% Thursday. The company announced that Eli Lilly has chosen FHD-909 for clinical development. Via Benzinga Foghorn Provides Pipeline Update on FHD-909 BRM Selective Inhibitor February 08, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Highlights Clinical Program Updates and Research Progress and Provides Strategic Objectives for 2024 January 08, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces CFO Departure January 03, 2024 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces Clinical Data from Phase 1 Study of FHD-286, a Novel BRG1/BRM Inhibitor, in Patients with Advanced Hematologic Malignancies, to be Presented at American Society of Hematology Annual Meeting December 01, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Provides Third Quarter 2023 Financial and Corporate Update November 02, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics to Present at Upcoming Conferences Including New Preclinical Data from EP300 and CBP Selective Degrader Programs October 24, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire Foghorn Therapeutics Announces Clinical Data From Phase 1 Study of FHD-286 in Metastatic Uveal Melanoma to Be Presented at ESMO Congress October 13, 2023 From Foghorn Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.